MIMS August prescribing update
- Exenatide (Bydureon) is an extended release microsphere formulation of exenatide. It is a glucagon-like peptide-1 (GLP-1) receptor agonist that exhibits several antihyperglycaemic actions of GLP-1.
Exenatide suppresses glucagon secretion which is known to be inappropriately elevated in type 2 diabetes.
It is indicated for the treatment of type 2 diabetes in combination with metformin or sulfonylurea or metformin and sulfonylurea in patients who have not achieved adequate glycaemic control.
It is contraindicated in patients with end-stage renal disease or severe renal impairment (creatinine clearance < 30mL/min).
It is available as a once weekly powder for injection supplied in a carton containing four single dose kits.